Authors: B Kampmann U Okomo
Published in: The Lancet
Given the success of COVID-19 vaccines in preventing death and severe disease in adults and their impact on community transmission, use in children and young people (CYP) inevitably requires consideration. Although severe COVID-19 is rare in CYP, they are affected by SARS-CoV-2 infection and the impacts of the COVID-19 pandemic, including education, mental health, and general wellbeing.
As of late July, 2021, no COVID-19 vaccine is recommended for children younger than 12 years and safety and efficacy data from phase 3 clinical trials are so far limited: 1131 CYP aged 12–15 years received the Pfizer–BioNTech mRNA vaccine and safety data are available from phase 1 and 2 trials of Sinovac’s inactivated CoronaVac vaccine in 438 children aged 3–17 years.
Read full comment